Advertisement

Index by Author

November 1994; 43 (11)
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z

A

  1. Aro, A

    • The risk to develop NIDDM is related to the fatty acid composition of the serum cholesterol esters. Diabetes November 1994 43:1353-1357; doi:10.2337/diabetes.43.11.1353

B

  1. Berglund, L

    • The risk to develop NIDDM is related to the fatty acid composition of the serum cholesterol esters. Diabetes November 1994 43:1353-1357; doi:10.2337/diabetes.43.11.1353

  2. Bergman, R N

    • Repeatability of insulin sensitivity and glucose effectiveness from the minimal model. Implications for study design. Diabetes November 1994 43:1365-1371; doi:10.2337/diabetes.43.11.1365

  3. Bingley, P J

    • Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes November 1994 43:1304-1310; doi:10.2337/diabetes.43.11.1304

  4. Blech, W

    • Intraportal transplantation of pancreatic islets into livers of diabetic rats. Reinnervation of islets and regulation of insulin secretion by the hepatic sympathetic nerves. Diabetes November 1994 43:1345-1352; doi:10.2337/diabetes.43.11.1345

  5. Bonfanti, R

    • Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes November 1994 43:1304-1310; doi:10.2337/diabetes.43.11.1304

  6. Bonifacio, E

    • Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes November 1994 43:1304-1310; doi:10.2337/diabetes.43.11.1304

  7. Bonner-Weir, S

    • Beneficial influence of glycemic control upon the growth and function of transplanted islets. Diabetes November 1994 43:1334-1339; doi:10.2337/diabetes.43.11.1334

  8. Bottazzo, G F

    • Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes November 1994 43:1304-1310; doi:10.2337/diabetes.43.11.1304

  9. Bouwens, L

    • Cytokeratins as markers of ductal cell differentiation and islet neogenesis in the neonatal rat pancreas. Diabetes November 1994 43:1279-1283; doi:10.2337/diabetes.43.11.1279

  10. Buchanan, T A

    • Repeatability of insulin sensitivity and glucose effectiveness from the minimal model. Implications for study design. Diabetes November 1994 43:1365-1371; doi:10.2337/diabetes.43.11.1365

  11. Bursell, S E

    • Normalization of diacylglycerol-protein kinase C activation by vitamin E in aorta of diabetic rats and cultured rat smooth muscle cells exposed to elevated glucose levels. Diabetes November 1994 43:1372-1377; doi:10.2337/diabetes.43.11.1372

C

  1. Christie, M R

    • Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes November 1994 43:1304-1310; doi:10.2337/diabetes.43.11.1304

  2. Cossel, L

    • Intraportal transplantation of pancreatic islets into livers of diabetic rats. Reinnervation of islets and regulation of insulin secretion by the hepatic sympathetic nerves. Diabetes November 1994 43:1345-1352; doi:10.2337/diabetes.43.11.1345

  3. Cryer, P

    • Effect of hyperketonemia and hyperlacticacidemia on symptoms, cognitive dysfunction, and counterregulatory hormone responses during hypoglycemia in normal humans. Diabetes November 1994 43:1311-1317; doi:10.2337/diabetes.43.11.1311

  4. Cryer, P E

    • Banting Lecture. Hypoglycemia: the limiting factor in the management of IDDM. Diabetes November 1994 43:1378-1389; doi:10.2337/diabetes.43.11.1378

D

  1. De Blay, E

    • Cytokeratins as markers of ductal cell differentiation and islet neogenesis in the neonatal rat pancreas. Diabetes November 1994 43:1279-1283; doi:10.2337/diabetes.43.11.1279

  2. Durinovic-Bellò, I

    • HLA-DQ-restricted, islet-specific T-cell clones of a type I diabetic patient. T-cell receptor sequence similarities to insulitis-inducing T-cells of nonobese diabetic mice. Diabetes November 1994 43:1318-1325; doi:10.2337/diabetes.43.11.1318

  3. Dyrberg, T

    • Glutamic acid decarboxylase (GAD65) autoantibodies in prediction of beta-cell function and remission in recent-onset IDDM after cyclosporin treatment. The Canadian-European Randomized Control Trial Group. Diabetes November 1994 43:1291-1296; doi:10.2337/diabetes.43.11.1291

F

  1. Ferber, S

    • STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes November 1994 43:1326-1333; doi:10.2337/diabetes.43.11.1326

  2. Fioretto, P

    • Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. Diabetes November 1994 43:1358-1364; doi:10.2337/diabetes.43.11.1358

  3. Fisher, S

    • Importance of substrate changes in the decrease of hepatic glucose cycling during insulin infusion and declining glycemia in the depancreatized dog. Diabetes November 1994 43:1284-1290; doi:10.2337/diabetes.43.11.1284

  4. Fonte, M T

    • Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes November 1994 43:1304-1310; doi:10.2337/diabetes.43.11.1304

G

  1. Gale, E A

    • Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes November 1994 43:1304-1310; doi:10.2337/diabetes.43.11.1304

  2. Gardemann, A

    • Intraportal transplantation of pancreatic islets into livers of diabetic rats. Reinnervation of islets and regulation of insulin secretion by the hepatic sympathetic nerves. Diabetes November 1994 43:1345-1352; doi:10.2337/diabetes.43.11.1345

  3. Gerich, J

    • Effect of hyperketonemia and hyperlacticacidemia on symptoms, cognitive dysfunction, and counterregulatory hormone responses during hypoglycemia in normal humans. Diabetes November 1994 43:1311-1317; doi:10.2337/diabetes.43.11.1311

  4. Giacca, A

    • Importance of substrate changes in the decrease of hepatic glucose cycling during insulin infusion and declining glycemia in the depancreatized dog. Diabetes November 1994 43:1284-1290; doi:10.2337/diabetes.43.11.1284

  5. Grosse, V

    • Intraportal transplantation of pancreatic islets into livers of diabetic rats. Reinnervation of islets and regulation of insulin secretion by the hepatic sympathetic nerves. Diabetes November 1994 43:1345-1352; doi:10.2337/diabetes.43.11.1345

H

  1. Hahn, H J

    • Intraportal transplantation of pancreatic islets into livers of diabetic rats. Reinnervation of islets and regulation of insulin secretion by the hepatic sympathetic nerves. Diabetes November 1994 43:1345-1352; doi:10.2337/diabetes.43.11.1345

  2. Henriksson, J

    • Regulation of skeletal muscle blood flow during acute insulin-induced hypoglycemia in the rat. Diabetes November 1994 43:1340-1344; doi:10.2337/diabetes.43.11.1340

  3. Hickner, R C

    • Regulation of skeletal muscle blood flow during acute insulin-induced hypoglycemia in the rat. Diabetes November 1994 43:1340-1344; doi:10.2337/diabetes.43.11.1340

  4. Hildebrandt, W

    • Intraportal transplantation of pancreatic islets into livers of diabetic rats. Reinnervation of islets and regulation of insulin secretion by the hepatic sympathetic nerves. Diabetes November 1994 43:1345-1352; doi:10.2337/diabetes.43.11.1345

  5. Hotamisligil, G S

    • Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes November 1994 43:1271-1278; doi:10.2337/diabetes.43.11.1271

J

  1. Johnson, J H

    • STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes November 1994 43:1326-1333; doi:10.2337/diabetes.43.11.1326

  2. Juang, J H

    • Beneficial influence of glycemic control upon the growth and function of transplanted islets. Diabetes November 1994 43:1334-1339; doi:10.2337/diabetes.43.11.1334

  3. Jungermann, K

    • Intraportal transplantation of pancreatic islets into livers of diabetic rats. Reinnervation of islets and regulation of insulin secretion by the hepatic sympathetic nerves. Diabetes November 1994 43:1345-1352; doi:10.2337/diabetes.43.11.1345

K

  1. Karlsen, A E

    • Glutamic acid decarboxylase (GAD65) autoantibodies in prediction of beta-cell function and remission in recent-onset IDDM after cyclosporin treatment. The Canadian-European Randomized Control Trial Group. Diabetes November 1994 43:1291-1296; doi:10.2337/diabetes.43.11.1291

  2. King, G L

    • Normalization of diacylglycerol-protein kinase C activation by vitamin E in aorta of diabetic rats and cultured rat smooth muscle cells exposed to elevated glucose levels. Diabetes November 1994 43:1372-1377; doi:10.2337/diabetes.43.11.1372

  3. Klöppel, G

    • Cytokeratins as markers of ductal cell differentiation and islet neogenesis in the neonatal rat pancreas. Diabetes November 1994 43:1279-1283; doi:10.2337/diabetes.43.11.1279

  4. Kunisaki, M

    • Normalization of diacylglycerol-protein kinase C activation by vitamin E in aorta of diabetic rats and cultured rat smooth muscle cells exposed to elevated glucose levels. Diabetes November 1994 43:1372-1377; doi:10.2337/diabetes.43.11.1372

L

  1. Lithell, H

    • The risk to develop NIDDM is related to the fatty acid composition of the serum cholesterol esters. Diabetes November 1994 43:1353-1357; doi:10.2337/diabetes.43.11.1353

M

  1. Mandrup-Poulsen, T

    • Glutamic acid decarboxylase (GAD65) autoantibodies in prediction of beta-cell function and remission in recent-onset IDDM after cyclosporin treatment. The Canadian-European Randomized Control Trial Group. Diabetes November 1994 43:1291-1296; doi:10.2337/diabetes.43.11.1291

  2. Mauer, M

    • Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. Diabetes November 1994 43:1358-1364; doi:10.2337/diabetes.43.11.1358

  3. Michelsen, B

    • Glutamic acid decarboxylase (GAD65) autoantibodies in prediction of beta-cell function and remission in recent-onset IDDM after cyclosporin treatment. The Canadian-European Randomized Control Trial Group. Diabetes November 1994 43:1291-1296; doi:10.2337/diabetes.43.11.1291

  4. Mitrakou, A

    • Effect of hyperketonemia and hyperlacticacidemia on symptoms, cognitive dysfunction, and counterregulatory hormone responses during hypoglycemia in normal humans. Diabetes November 1994 43:1311-1317; doi:10.2337/diabetes.43.11.1311

  5. Mokan, M

    • Effect of hyperketonemia and hyperlacticacidemia on symptoms, cognitive dysfunction, and counterregulatory hormone responses during hypoglycemia in normal humans. Diabetes November 1994 43:1311-1317; doi:10.2337/diabetes.43.11.1311

  6. Murray, J

    • Repeatability of insulin sensitivity and glucose effectiveness from the minimal model. Implications for study design. Diabetes November 1994 43:1365-1371; doi:10.2337/diabetes.43.11.1365

  7. Mølvig, J

    • Glutamic acid decarboxylase (GAD65) autoantibodies in prediction of beta-cell function and remission in recent-onset IDDM after cyclosporin treatment. The Canadian-European Randomized Control Trial Group. Diabetes November 1994 43:1291-1296; doi:10.2337/diabetes.43.11.1291

N

  1. Nawata, H

    • Normalization of diacylglycerol-protein kinase C activation by vitamin E in aorta of diabetic rats and cultured rat smooth muscle cells exposed to elevated glucose levels. Diabetes November 1994 43:1372-1377; doi:10.2337/diabetes.43.11.1372

  2. Nerup, J

    • Glutamic acid decarboxylase (GAD65) autoantibodies in prediction of beta-cell function and remission in recent-onset IDDM after cyclosporin treatment. The Canadian-European Randomized Control Trial Group. Diabetes November 1994 43:1291-1296; doi:10.2337/diabetes.43.11.1291

  3. Newgard, C B

    • STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes November 1994 43:1326-1333; doi:10.2337/diabetes.43.11.1326

P

  1. Petersen, J S

    • Glutamic acid decarboxylase (GAD65) autoantibodies in prediction of beta-cell function and remission in recent-onset IDDM after cyclosporin treatment. The Canadian-European Randomized Control Trial Group. Diabetes November 1994 43:1291-1296; doi:10.2337/diabetes.43.11.1291

  2. Pipeleers, D G

    • Cytokeratins as markers of ductal cell differentiation and islet neogenesis in the neonatal rat pancreas. Diabetes November 1994 43:1279-1283; doi:10.2337/diabetes.43.11.1279

R

  1. Roth, R A

    • Insulin receptor signaling in Madin-Darby canine kidney cells overexpressing the human insulin receptor. Diabetes November 1994 43:1297-1303; doi:10.2337/diabetes.43.11.1297

S

  1. Salminen, I

    • The risk to develop NIDDM is related to the fatty acid composition of the serum cholesterol esters. Diabetes November 1994 43:1353-1357; doi:10.2337/diabetes.43.11.1353

  2. Schendel, D J

    • HLA-DQ-restricted, islet-specific T-cell clones of a type I diabetic patient. T-cell receptor sequence similarities to insulitis-inducing T-cells of nonobese diabetic mice. Diabetes November 1994 43:1318-1325; doi:10.2337/diabetes.43.11.1318

  3. Schnedl, W J

    • STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes November 1994 43:1326-1333; doi:10.2337/diabetes.43.11.1326

  4. Shattock, M

    • Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes November 1994 43:1304-1310; doi:10.2337/diabetes.43.11.1304

  5. Shi, Z Q

    • Importance of substrate changes in the decrease of hepatic glucose cycling during insulin infusion and declining glycemia in the depancreatized dog. Diabetes November 1994 43:1284-1290; doi:10.2337/diabetes.43.11.1284

  6. Skarfors, E

    • The risk to develop NIDDM is related to the fatty acid composition of the serum cholesterol esters. Diabetes November 1994 43:1353-1357; doi:10.2337/diabetes.43.11.1353

  7. Spiegelman, B M

    • Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes November 1994 43:1271-1278; doi:10.2337/diabetes.43.11.1271

  8. Steffes, M W

    • Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. Diabetes November 1994 43:1358-1364; doi:10.2337/diabetes.43.11.1358

  9. Steil, G M

    • Repeatability of insulin sensitivity and glucose effectiveness from the minimal model. Implications for study design. Diabetes November 1994 43:1365-1371; doi:10.2337/diabetes.43.11.1365

  10. Steinle, A

    • HLA-DQ-restricted, islet-specific T-cell clones of a type I diabetic patient. T-cell receptor sequence similarities to insulitis-inducing T-cells of nonobese diabetic mice. Diabetes November 1994 43:1318-1325; doi:10.2337/diabetes.43.11.1318

U

  1. Umeda, F

    • Normalization of diacylglycerol-protein kinase C activation by vitamin E in aorta of diabetic rats and cultured rat smooth muscle cells exposed to elevated glucose levels. Diabetes November 1994 43:1372-1377; doi:10.2337/diabetes.43.11.1372

  2. Ungerstedt, U

    • Regulation of skeletal muscle blood flow during acute insulin-induced hypoglycemia in the rat. Diabetes November 1994 43:1340-1344; doi:10.2337/diabetes.43.11.1340

V

  1. van de Werve, G

    • Importance of substrate changes in the decrease of hepatic glucose cycling during insulin infusion and declining glycemia in the depancreatized dog. Diabetes November 1994 43:1284-1290; doi:10.2337/diabetes.43.11.1284

  2. Veneman, T

    • Effect of hyperketonemia and hyperlacticacidemia on symptoms, cognitive dysfunction, and counterregulatory hormone responses during hypoglycemia in normal humans. Diabetes November 1994 43:1311-1317; doi:10.2337/diabetes.43.11.1311

  3. Vessby, B

    • The risk to develop NIDDM is related to the fatty acid composition of the serum cholesterol esters. Diabetes November 1994 43:1353-1357; doi:10.2337/diabetes.43.11.1353

  4. Vidal, H

    • Importance of substrate changes in the decrease of hepatic glucose cycling during insulin infusion and declining glycemia in the depancreatized dog. Diabetes November 1994 43:1284-1290; doi:10.2337/diabetes.43.11.1284

  5. Vranic, M

    • Importance of substrate changes in the decrease of hepatic glucose cycling during insulin infusion and declining glycemia in the depancreatized dog. Diabetes November 1994 43:1284-1290; doi:10.2337/diabetes.43.11.1284

W

  1. Wang, R N

    • Cytokeratins as markers of ductal cell differentiation and islet neogenesis in the neonatal rat pancreas. Diabetes November 1994 43:1279-1283; doi:10.2337/diabetes.43.11.1279

  2. Weir, G C

    • Beneficial influence of glycemic control upon the growth and function of transplanted islets. Diabetes November 1994 43:1334-1339; doi:10.2337/diabetes.43.11.1334

  3. Wohlrab, F

    • Intraportal transplantation of pancreatic islets into livers of diabetic rats. Reinnervation of islets and regulation of insulin secretion by the hepatic sympathetic nerves. Diabetes November 1994 43:1345-1352; doi:10.2337/diabetes.43.11.1345

  4. Wu, Y J

    • Beneficial influence of glycemic control upon the growth and function of transplanted islets. Diabetes November 1994 43:1334-1339; doi:10.2337/diabetes.43.11.1334

Y

  1. Yeh, T C

    • Insulin receptor signaling in Madin-Darby canine kidney cells overexpressing the human insulin receptor. Diabetes November 1994 43:1297-1303; doi:10.2337/diabetes.43.11.1297

Z

  1. Ziegler, A G

    • HLA-DQ-restricted, islet-specific T-cell clones of a type I diabetic patient. T-cell receptor sequence similarities to insulitis-inducing T-cells of nonobese diabetic mice. Diabetes November 1994 43:1318-1325; doi:10.2337/diabetes.43.11.1318

Current Issue

  1. February 2012, 61 (2)
  1. Current Issue
  1. Alert me to new issues of Diabetes
Advertisement